IL6 and cholangiocarcinoma: Although the addition of IL-6 did not alter the levels of pJAK2 and pSTAT3 in all three CCA cell lines treated with 0% CH-CM, it significantly increased pJAK2 levels in both KKU213A and KKU213B treated with 75% CH-CM (Fig. 7).